HC Wainwright Forecasts Liquidia FY2030 Earnings

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for Liquidia in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst A. Fein expects that the company will post earnings per share of $9.85 for the year. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share.

A number of other analysts have also weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $49.00 price objective on shares of Liquidia in a research report on Friday, January 9th. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a report on Sunday, January 18th. Jefferies Financial Group increased their price target on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, January 13th. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Liquidia in a research note on Wednesday, February 25th. Finally, Zacks Research lowered shares of Liquidia from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Price Performance

Liquidia stock opened at $34.38 on Wednesday. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia has a 52-week low of $11.26 and a 52-week high of $46.67. The firm has a market cap of $2.99 billion, a PE ratio of -23.87, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company’s 50 day moving average is $37.09 and its two-hundred day moving average is $30.81.

Insider Transactions at Liquidia

In related news, General Counsel Russell Schundler sold 27,289 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the transaction, the general counsel directly owned 579,394 shares of the company’s stock, valued at $21,686,717.42. This trade represents a 4.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Scott Moomaw sold 20,533 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $768,550.19. Following the completion of the sale, the insider directly owned 154,514 shares of the company’s stock, valued at approximately $5,783,459.02. This trade represents a 11.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 212,534 shares of company stock valued at $7,964,719 over the last three months. 26.50% of the stock is owned by corporate insiders.

Institutional Trading of Liquidia

A number of hedge funds and other institutional investors have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Liquidia in the 4th quarter valued at about $25,000. NewEdge Advisors LLC purchased a new stake in Liquidia in the second quarter valued at approximately $25,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Liquidia in the third quarter valued at approximately $30,000. FNY Investment Advisers LLC purchased a new position in shares of Liquidia during the third quarter worth approximately $34,000. Finally, Covestor Ltd increased its holdings in shares of Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after acquiring an additional 359 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).